Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neglected tropical diseases in conflict zones: devastating consequences of a lack of inclusion.

International health·2026
Same author

The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities.

Parasites & vectors·2025
Same author

Cutaneous leishmaniasis in Afghanistan.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2025
Same author

Kala-azar elimination in India: reflections on success and sustainability.

International health·2025
Same author

Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India.

PLoS neglected tropical diseases·2025
Same author

Prediction of visceral leishmaniasis development in a highly exposed HIV cohort in Ethiopia based on Leishmania infection markers: results from the PreLeisH study.

EBioMedicine·2024
Same journal

Acquired haemophilia B in Kyasanur Forest disease: a case series of isolated prolonged activated partial thromboplastin time.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2026
Same journal

Integrated and sustainable community approach to malaria prevention in Gulu District, Northern Uganda.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2026
Same journal

Long-lasting helminthic infection in African migrants to Israel - Lessons from the field.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2026
Same journal

Comment on: Impact of Wolbachia-infected Aedes aegypti on dengue incidence in endemic regions.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2026
Same journal

Bridging a critical gap in leishmaniasis control: focus on immature sandfly ecology.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2026
Same journal

Parents' challenges in identifying offending snakes during paediatric snakebites in Sri Lanka: a qualitative study.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

Paromomycin.

Robert N Davidson1, Margriet den Boer, Koert Ritmeijer

  • 1Department of Infection and Tropical Medicine, Lister Unit, Northwick Park Hospital, Harrow, Middlesex, UK. r.n.davidson@ic.ac.uk

Transactions of the Royal Society of Tropical Medicine and Hygiene
|October 25, 2008
PubMed
Summary
This summary is machine-generated.

Paromomycin is an affordable treatment for visceral leishmaniasis (VL). Combination therapy with paromomycin prevents drug resistance and ensures its long-term effectiveness for treating VL.

More Related Videos

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

Techniques for Imaging Prometaphase and Metaphase of Meiosis I in Fixed Drosophila Oocytes
09:11

Techniques for Imaging Prometaphase and Metaphase of Meiosis I in Fixed Drosophila Oocytes

Published on: October 31, 2016

Related Experiment Videos

Last Updated: Jun 28, 2026

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

Techniques for Imaging Prometaphase and Metaphase of Meiosis I in Fixed Drosophila Oocytes
09:11

Techniques for Imaging Prometaphase and Metaphase of Meiosis I in Fixed Drosophila Oocytes

Published on: October 31, 2016

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Tropical Medicine

Background:

  • Paromomycin, an aminoglycoside, exhibits activity against various bacteria, protozoa, and cestodes.
  • While no longer widely used as an antibiotic, paromomycin was approved in India in 2007 for visceral leishmaniasis (VL).
  • Ongoing studies in Africa and India are evaluating paromomycin for VL treatment, both as monotherapy and in combination regimens.

Purpose of the Study:

  • To assess the efficacy and safety of paromomycin for visceral leishmaniasis.
  • To explore the role of paromomycin in combination therapy to prevent drug resistance.
  • To recommend strategies for the sustainable use of paromomycin in VL treatment.

Main Methods:

  • Clinical trials evaluating paromomycin monotherapy and combination therapy for VL.
  • Phase IV study in India and ongoing research in Africa by DNDi and IOIH.
  • Analysis of treatment outcomes, including efficacy and survival rates.

Main Results:

  • Paromomycin is an effective, well-tolerated, and affordable VL treatment.
  • Combination therapy with sodium stibogluconate demonstrates efficacy in both African and Indian VL cases.
  • Combination therapy improves survival rates in African VL patients.

Conclusions:

  • Paromomycin, particularly in combination therapy, is crucial for preventing drug-resistant leishmaniasis in endemic areas.
  • Further clinical trials investigating diverse combination therapies are essential.
  • Regulated distribution, preferably through the public sector, will ensure paromomycin's sustained availability for VL treatment.